FY2021 EPS Estimates for Allergan plc Raised by Analyst (AGN)

Allergan plc (NYSE:AGN) – Investment analysts at Gabelli lifted their FY2021 earnings per share (EPS) estimates for shares of Allergan in a report issued on Wednesday. Gabelli analyst K. Kedra now expects that the company will earn $21.45 per share for the year, up from their prior forecast of $21.40.

Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, topping the Zacks’ consensus estimate of $4.74 by $0.12. The company had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. Allergan’s revenue was up 12.0% compared to the same quarter last year. During the same quarter last year, the firm posted $3.90 earnings per share.

A number of other equities research analysts have also commented on the company. Argus lowered Allergan from a “buy” rating to a “hold” rating and dropped their price target for the stock from $256.80 to $160.07 in a research report on Thursday, December 7th. JPMorgan Chase & Co. set a $275.00 price target on Allergan and gave the stock a “buy” rating in a research report on Sunday, October 22nd. Deutsche Bank reaffirmed a “buy” rating and set a $215.00 price target on shares of Allergan in a research report on Tuesday, January 9th. Zacks Investment Research lowered Allergan from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Finally, Vetr lowered Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 price target on the stock. in a research report on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $227.23.

Allergan (NYSE AGN) traded down $1.43 during midday trading on Friday, hitting $162.77. The stock had a trading volume of 4,240,391 shares, compared to its average volume of 3,128,767. The firm has a market capitalization of $54,610.00, a price-to-earnings ratio of -13.58, a P/E/G ratio of 1.26 and a beta of 1.19. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.08 and a current ratio of 2.04. Allergan has a 52 week low of $157.70 and a 52 week high of $256.80.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be given a dividend of $0.72 per share. This is a positive change from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a dividend yield of 1.77%. Allergan’s payout ratio is -23.35%.

In related news, Director Chris W. Bodine purchased 3,030 shares of the stock in a transaction on Thursday, December 7th. The shares were purchased at an average price of $164.77 per share, with a total value of $499,253.10. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Brent L. Saunders purchased 4,600 shares of the stock in a transaction on Wednesday, December 6th. The shares were bought at an average cost of $164.74 per share, for a total transaction of $757,804.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 17,630 shares of company stock worth $2,890,057 in the last ninety days. Insiders own 0.36% of the company’s stock.

Several large investors have recently bought and sold shares of AGN. Itau Unibanco Holding S.A. boosted its stake in shares of Allergan by 108.4% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,694 shares of the company’s stock worth $277,000 after acquiring an additional 881 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Allergan by 479.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,768 shares of the company’s stock worth $289,000 after acquiring an additional 1,463 shares during the period. UBS Asset Management Americas Inc. boosted its stake in shares of Allergan by 13.6% during the 4th quarter. UBS Asset Management Americas Inc. now owns 1,763,209 shares of the company’s stock worth $288,426,000 after acquiring an additional 210,962 shares during the period. Rhumbline Advisers boosted its stake in shares of Allergan by 2.6% during the 4th quarter. Rhumbline Advisers now owns 534,738 shares of the company’s stock worth $87,472,000 after acquiring an additional 13,462 shares during the period. Finally, Levin Capital Strategies L.P. boosted its stake in shares of Allergan by 44.9% during the 4th quarter. Levin Capital Strategies L.P. now owns 654,173 shares of the company’s stock worth $107,010,000 after acquiring an additional 202,643 shares during the period. 80.23% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “FY2021 EPS Estimates for Allergan plc Raised by Analyst (AGN)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/09/fy2021-eps-estimates-for-allergan-plc-raised-by-analyst-agn.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Earnings History and Estimates for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply